The landscape of cancer care is undergoing a significant transition, moving away from centralized hospital-based management toward a more integrated, decentralized model where community pharmacists play a pivotal role. This shift is primarily driven by the increasing availability of oral anticancer therapies (OACTs), which allow patients to manage complex treatments from the comfort of their homes. However, this transition necessitates a seamless bridge between hospital specialists and community practitioners. To address these challenges, the Oncofficine project in the Nouvelle-Aquitaine region of France has emerged as a groundbreaking initiative, spearheaded by Dr. Barbara Lortal, a hospital pharmacist at the Institut Bergonié, and Valérie Bellamy, a dedicated patient partner. By combining professional medical expertise with the lived experience of patients, the project aims to standardize care, improve treatment adherence, and dismantle the perceived taboos surrounding oncology in a retail pharmacy setting.

The Evolution of the Oncology Care Pathway

Historically, the administration of cytotoxic treatments was strictly confined to hospital settings, under the direct supervision of oncologists and hospital pharmacists. With the advent of targeted therapies and oral chemotherapies, the burden of monitoring these treatments has partially shifted to community pharmacies. While this offers patients greater convenience, it introduces risks related to drug interactions, toxicity management, and medication adherence.

In response, regulatory bodies and healthcare systems have begun to formalize the role of the community pharmacist through "conventioned interviews"—structured consultations designed to educate patients on their treatment regimens, identify side effects, and ensure adherence. Despite the clear legislative framework for these interviews, implementation has been inconsistent. Many community pharmacists, despite their clinical training, report feeling inadequately prepared or hesitant to engage deeply with oncology patients, often citing a lack of confidence or a fear of navigating the sensitive psychological landscape of cancer.

Genesis of the Oncofficine Project: A Collaborative Timeline

The roots of the Oncofficine project can be traced back to an unconventional meeting three years ago. Valérie Bellamy, while pursuing a university degree as a "patient partner" at Sorbonne University, sought an internship within the pharmacy department of the Institut Bergonié. Dr. Barbara Lortal, recognizing the untapped potential of integrating the patient’s perspective into clinical pharmacy operations, accepted the challenge.

This initial collaboration challenged the traditional hierarchical structure of hospital departments. By integrating a patient partner directly into the clinical workflow, the team identified a critical gap: the disconnect between the "high-tech" environment of the hospital and the "proximité" (proximity) of the local pharmacy.

Between 2022 and 2024, the duo initiated a "go-to-the-field" strategy, traveling across the Nouvelle-Aquitaine region—visiting towns such as Dax, Niort, and Pau—to engage directly with local pharmacy owners. The project’s objective was to provide these professionals with the necessary tools, confidence, and documentation to transform their practice. This grassroots effort was supported by the Regional Health Agency (ARS) and the Omédit (Observatory of Medicines, Medical Devices, and Therapeutic Innovations), acknowledging the initiative’s potential to improve regional health outcomes.

Bridging the Gap: Data and Methodology

The success of the Oncofficine initiative rests on its multi-faceted approach to education and support. The core of the program is the Oncofficine digital platform, which serves as a central repository for resources.

  1. Standardized Clinical Resources: The platform provides pharmacists with up-to-date documentation on OACTs, focusing on side-effect profiles, common drug-drug interactions, and management protocols for non-specialists.
  2. Interactive Training: Through a "Serious Game" format, pharmacists are immersed in simulated patient scenarios. This pedagogical approach helps them practice communication techniques, specifically focusing on how to initiate difficult conversations about a cancer diagnosis or treatment failure.
  3. Continuing Professional Development (DPC): The training modules are accredited, providing pharmacists with formal recognition for their participation in the program, which is essential for professional advancement in the French healthcare system.

The project addresses a critical data point: while community pharmacists are the most accessible healthcare providers, the uptake of structured oncology interviews remains lower than the frequency of prescriptions dispensed. By humanizing the process through the inclusion of patient partners like Bellamy, the project effectively reduces the "fear factor" that prevents many pharmacists from fully participating in the oncology pathway.

The Role of the Patient Partner in Ambulatory Care

The inclusion of a patient partner—someone who has navigated the disease and the healthcare system—is perhaps the most innovative aspect of the Oncofficine project. In an ambulatory care setting, the patient partner serves as a bridge between the clinical rigidity of the hospital and the personal, everyday reality of the patient.

"The patient partner is still a relatively new concept in ambulatory care," explains Valérie Bellamy. "We do not wear white coats, yet we possess a specific kind of knowledge derived from our experience. When we speak to pharmacists, we are not just teaching them about medication; we are teaching them about the patient’s journey."

This perspective is crucial for helping pharmacists understand the psychological barriers that patients face, such as the anxiety of self-administering potent drugs at home or the challenge of managing multiple comorbidities. By normalizing the dialogue, the patient partner helps the pharmacist transition from a dispenser of medication to an active participant in the therapeutic alliance.

Implications for Regional and National Healthcare

The implications of the Oncofficine model extend far beyond the borders of Nouvelle-Aquitaine. As cancer becomes a chronic condition for many, the demand for high-quality, local care will only increase.

  • Network Integration: The project promotes the use of Communautés Professionnelles Territoriales de Santé (CPTS), which are professional territorial health communities. By aligning pharmacists with these groups, the initiative ensures that communication flows effectively between general practitioners, hospital specialists, and pharmacists.
  • Economic Sustainability: While funding remains a challenge—particularly concerning the remuneration for the time spent by hospital staff to mentor community pharmacists—the long-term economic argument is compelling. Improved adherence to expensive oral cancer treatments leads to better clinical outcomes and fewer hospital readmissions due to avoidable side effects or treatment errors.
  • Interprofessional Learning: The collaboration proves that the exchange of knowledge is bidirectional. While the hospital pharmacist provides the latest technical knowledge on novel molecular treatments, the community pharmacist brings valuable expertise on dermocosmetics, over-the-counter care, and patient-specific habits that hospital staff rarely observe.

Future Perspectives and Scaling the Initiative

The current phase of the Oncofficine project focuses on scaling. With the continued support of the ARS and Omédit, the founders are looking to recruit a broader network of hospital pharmacists and patient partners. The goal is to move away from a two-person operation to a regional network of "binômes" (pairs) capable of deploying training and support services across all districts of the region.

"We have proven the concept," says Dr. Lortal. "The next step is to standardize this as a regional norm. We need to empower pharmacists to stop seeing cancer as a taboo subject and start seeing it as an essential, everyday component of their professional mission."

The project also aims to address the digital divide and the logistical difficulties of reaching pharmacists in rural areas. By leveraging the online platform, they ensure that even the most isolated practitioner can access the same level of training and documentation as those in major urban centers like Bordeaux.

Conclusion

The Oncofficine project stands as a testament to the power of interdisciplinary collaboration. By dismantling the silos that traditionally separate hospital and city-based care, the initiative has created a blueprint for how healthcare systems can adapt to the modern realities of oncology. The success of the project is not measured solely by the number of clicks on a website or the number of pharmacists trained, but by the tangible improvement in the quality of care experienced by patients who, in their most vulnerable moments, find a knowledgeable, empathetic, and confident partner in their local pharmacy. As the program continues to grow, it serves as a powerful reminder that the most effective advancements in medicine often come from simply listening to those who know the system best: the providers, the patients, and the partners who work between them.

By Asro

SanteNews

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.